ClinicalTrials.gg
RecruitingNCT05563792OPTIONSUpdated Oct 15, 2026

Options for Pain Management Using Nonpharmacological Strategies

An interventional study of Options for Pain Management using Non-medication Strategies in Pain, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Pain by VA Office of Research and Development — 13 open to participants now, 15 under way, 1 of them phase 3. Pain · VA Office of Research and Development.

Planned enrollment
8th of 46
296 · median 194
Started
2022
with 2 others
No phase
36 of 48
9 open now
Primary completion
2027-01
later than 2 of 14 live
Registered
38th of 48
by date

Among the 48 studies in Pain by VA Office of Research and Development, this one is the 8th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2022, is one of 36 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 38th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

13 of the 48 studies in Pain by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pain by VA Office of Research and Development, or all of them as a file.
02

Study summary

The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore the Veterans' values and goals and how different non-medication approaches may fit into these values and goals.

Read the detailed description

Non-pharmacological treatments (NPTs) for chronic pain are safe, effective, and widely available in VA. In response to the widespread harms associated with opioids and high-quality evidence supporting NPTs for chronic pain the Centers for Disease Control, American College of Physicians, Department of Defense, and Veterans Health Administration (VHA) released guidelines or adopted policies to move away from opioids toward multimodal approaches that prioritize evidence-based nonpharmacological pain treatments (NPTs) NPTs include both traditional (e.g., cognitive behavioral therapy, exercise/movement) and complementary/integrative health (CIH) (e.g., acupuncture, yoga) approaches. VA has been a leader in expanding access to these approaches, and in 2016 the Comprehensive Addiction and Recovery Act mandated that VA expand availability of CIH therapies. A survey published in 2021 revealed that this expansion has been successful. VA medical centers offered an average of 5 CIH approaches, with 63 sites offering at least 10. Expansion of CIH therapies has also been one of three key components of VA's Whole Health Initiative, implemented by VA's Office of Patient-Centered Care and Cultural Transformation (one of the investigators' operational partners). In addition, as a result of implementation in 2012, cognitive-behavioral therapy for chronic pain is available at 92% of VAs. Consequently, NPTs are widely available across VA.

Despite these efforts, pain remains a significant problem among Veterans. In 2017, 66% of Veterans reported pain, with 9% reporting severe pain. Compared to non-Veterans, Veterans had 1.5 times the odds of having severe pain, and Veterans aged 18-39 had 3 times the odds of having severe pain compared to non-Veterans of the same age. A survey of over 9,000 Veterans with pain, published in 2020, revealed that Veterans continue to report high pain levels. Veterans reported a past-week mean pain severity of 6.75 on a 0-10 scale and a mean of 6.8 different pain locations. Over half (56%) of Veterans reported the effectiveness of the Veterans' pain treatment as fair to poor, with only 12% rating the Veterans' pain treatment as very good or excellent. Continued opioid-related harms, high levels of Veteran-reported pain, and low satisfaction with pain care indicate that, despite VA efforts to improve pain management, additional efforts are needed to help Veterans effectively manage chronic pain using safe, evidence-based approaches.

03

Conditions studied

  • Pain

Keywords

  • Chronic Pain
  • Self management
  • Pain management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have musculoskeletal pain in the low back, cervical spine, or extremities (hip, knee, or shoulder) for at least 3 months
  • have at least moderate pain intensity and interference with function, defined by a score of 4 (possible range: 0-10) on the PEG, a 3-item measure of pain intensity, interference with enjoyment of life, and interference with general activity (obtained from phone screener)
  • have a primary care appointment scheduled or due in approximately the next three months
  • open to trying new pain treatments

Exclusion criteria

Exclusion Criteria:

  • a psychiatric hospitalization in the past 6 months
  • long-term opioid therapy
  • severe medical conditions likely precluding participation (e.g., NY Heart Association Class III or IV heart failure) which includes heart attack, stroke, and cancer, or
  • if the eligibility screener reveals cognitive impairment, defined by a score of >3 (possible range: 0-6) on cognitive screen (obtained from phone screener), or
  • if the eligibility screener reveals active suicidal ideation, or
  • severe hearing/speech impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
296 participants (estimated)

Study arms

  • Experimental
    OPTIONS Intervention Coaching

    Intervention participants will participate in a series of four coaching sessions focused on helping patients clarify their values and treatment goals, aligning these values and goals and their lifestyle with nonpharmacological treatment options, working on overcoming barriers to use and adherence of nonpharmacological treatment options (using motivational interviewing), and preparing patients to discuss these options with their primary care providers. A decision aid will be used during these coaching sessions.

    Behavioral: Options for Pain Management using Non-medication Strategies

  • No intervention
    OPTIONS Waitlist Control

    Participants randomized into waitlist control group will receive the intervention decision aid after completing the last survey at 9 months. Participants will also be offered the opportunity to have a brief 20-minute session with a member of the OPTIONS study staff to help walk them through this decision aid.

Interventions

  • BehavioralOptions for Pain Management using Non-medication Strategies

    The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.

    Also known as: OPTIONS

06

What researchers measure

Primary outcomes

  1. Pain Interference Brief Pain Inventory (BPI)

    The pain interference score from the Brief Pain Inventory averages seven ratings, 0 (does not interfere) to 10 (interferes completely), of interference with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Lower scores are better outcomes.

    Time frame: Change from baseline to 6 months

Secondary outcomes

  1. Use of Nonpharmacological and Self-Care Approaches (NSCAP)

    This measure was developed by members of the VA/DoD/NIH Pain Management Collaboratory, which is comprised of national experts in NPTs and is led by Dr. Robert Kerns of the VA PRIME Center. The NSCAP asks about use of 9 Non-pharmacological treatments , including the 6 included in the OPTIONS Decision Aid, and assesses details of use such as frequency and patients' judgments of effectiveness. Space is provided for additional Non-pharmacological treatments patients may be using.

    Time frame: Change from baseline to 6 months

  2. Patient Activation Measure (PAM)

    Patient activation will be measured with the 13-item Patient Activation Measure (PAM) Short Form, which assesses patient knowledge, skill, and confidence for self-management of one's chronic health condition. The PAM has good reliability ( =.87-.88) and validity in many studies, including our own.

    Time frame: Change from baseline to 6 months

  3. VR-12

    Health-related quality of life will be measured with the VR-12, a modified version of the Medical Outcomes Study SF-12. Internal consistency is high, ranging from =.87-.96.73

    Time frame: Change from baseline to 6 months

  4. Depression PHQ-8

    Depression will be measured with the widely-used 8-item PHQ-8

    Time frame: Change from baseline to 6 months

  5. Anxiety GAD-7

    Anxiety will be measured with the GAD-7, which has strong psychometric properties.

    Time frame: Change from baseline to 6 months

  6. Pain catastrophizing

    Pain catastrophizing will be measured with the 13-item Pain Catastrophizing Scale, which is a strong predictor of treatment response and has strong psychometric properties.

    Time frame: Change from baseline to 6 months

  7. Decisional Conflict Scale

    The decisional conflict scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty; and c) effective decision making.

    Time frame: Change from baseline to 6 months

07

Study locations

1 of 1 sites recruiting
  • Richard L. Roudebush VA Medical Center, Indianapolis, IN
    Indianapolis, Indiana 46202-2884, United States
    Recruiting
    • Angela L Rollins, PhD MS · ContactAngela.Rollins@va.gov · (317) 771-4023
    • Matthew J. Bair, MD MS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jan 2027, 50 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 50 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2026 → Jan 2027 and completion Oct 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 3, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Jan 31, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Oct 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jan 31, 2027
Oct 15, 2026
Study completion
Oct 31, 2026→Sep 30, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Sep 30, 2026→Jan 31, 2027
    Study completion Oct 31, 2026→Sep 30, 2027
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05563792
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Nov 1, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Marianne S Matthias, PhD MS BA
Contact
msmatthias@arizona.edu
(520) 626-6154
Matthew J. Bair, MD MS
principal investigator · Richard L. Roudebush VA Medical Center, Indianapolis, IN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion